Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.46 |
| ▸ | BRD4 | O60885 | 4/20 | 0.45 |
| ▸ | BRD2 | P25440 | 4/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.45 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2006988 | 0.96 | BRD4 (0.51) | OPRD1HRH3BRD4BRD2BRD3 | |
| SCHEMBL4054289 | 0.92 | BRD4 (0.45) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL2002214 | 0.91 | RHOC (0.41) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL12570153 | 0.89 | RAB9A (0.40) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL12570152 | 0.88 | RHOC (0.41) | BRD4BRD2BRD3BRDTALDH1A1 | |
| SCHEMBL2002379 | 0.87 | LMNA (0.47) | LMNARORC | |
| SCHEMBL2002378 | 0.87 | LMNA (0.47) | LMNARORC | |
| SCHEMBL13670322 | 0.87 | RORC (0.41) | BRD4BRD2BRD3BRDTRORC | |
| SCHEMBL2011173 | 0.86 | TDP1 (0.48) | BRD4ALDH1A1RORC | |
| SCHEMBL13669971 | 0.86 | TDP1 (0.48) | BRD4ALDH1A1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009120660-A2 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CNR1, CNR2, TRPV1 | OPRD1 88/4885HRH3 23/4885BRD4 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.